Investors > ASX Announcements

ASX Announcements

16-May-2022	Change of Director's Interest - Philip Powell

10-May-2022	IIQ Investor Presentation

9-May-2022	Change of Director's Interest - Dr Geoffrey Cumming

4-May-2022	Change of Director's Interest - Philip Powell

3-May-2022	INOVIQ Investor Briefing Invitation

3-May-2022	Australian Patent Granted for SubB2M Technology

2-May-2022	INOVIQ Key Manufacturing Agreement to Advance SubB2M tests

29-Apr-2022	IIQ Appendix 4C & Quarterly Activities Report - March 2022

26-Apr-2022	INOVIQ CSO Co-Authors Scientific Statement on Exosomes

21-Apr-2022	Notification of cessation of securities - IIQ

6-Apr-2022	Updated Investor Presentation

6-Apr-2022	SubB2M Paper Published in BMC Cancer Journal

5-Apr-2022	INOVIQ Engages ResearchDX to Develop & Validate SubB2M-Tests

1-Apr-2022	INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test

28-Mar-2022	Update on Legal Proceedings and BARD1 Autoantibody Program

25-Feb-2022	Appendix 4D and Half Year Financial Report

23-Feb-2022	Brazilian Patent Issued for Lung & Colorectal Cancer

31-Jan-2022	Notification regarding unquoted securities - IIQ

31-Jan-2022	Appendix 4C & Quarterly Activities Report

17-Jan-2022	US Patent Issued - BARD1 Breast & Ovarian Cancer Diagnosis

10-Jan-2022	INOVIQ Awarded Additional BTB Funding to Develop SubB2M test

29-Dec-2021	INOVIQ Appendix 4G and Corporate Governance Statement

24-Dec-2021	Chinese Patent Issued in BARD1 Patent Family for Lung Cancer

22-Dec-2021	Appendix 3Y - Change of Director's Interest Notice x 4

13-Dec-2021	Notification regarding unquoted securities - IIQ

8-Dec-2021	BARD1 Changes its Name to INOVIQ

7-Dec-2021	Cleansing Notice - Issue of Four Shares - Resolution 5 AGM

7-Dec-2021	Application for quotation of securities - BD1

2-Dec-2021	Application for quotation of securities - BD1

30-Nov-2021	Results of 2021 Annual General Meeting

29-Nov-2021	AGM Presentation

29-Nov-2021	New BARD1 Exosome Liquid Biopsy Project

25-Nov-2021	Application for quotation of securities - BD1

22-Nov-2021	Notification regarding unquoted securities - BD1

12-Nov-2021	US Patent Issued - BARD1 Patent Family Lung Cancer Diagnosis

10-Nov-2021	EXO-NET ANZSEV Presentation

10-Nov-2021	BARD1 Presenting at Bell Potter Healthcare Conference

10-Nov-2021	EXO-NET Presented at Virtual ANZSEV Symposium

9-Nov-2021	Jobkeeper Payment Notification

1-Nov-2021	Notice of Annual General Meeting/Proxy Form

29-Oct-2021	Ceasing to be a substantial holder

29-Oct-2021	Appendix 4G and Corporate Governance Statement

29-Oct-2021	Appendix 4C & Quarterly Activities Report

22-Oct-2021	Change of Director's Interest - Philip Powell

20-Oct-2021	Amended Remuneration Table Directors Report

11-Oct-2021	Notice required under listing rule 3.13.1

1-Oct-2021	Notification of cessation of securities - BD1

29-Sep-2021	2021 Annual Report

16-Sep-2021	BARD1 Appoints New CSO

7-Sep-2021	Notification of cessation of securities - BD1

31-Aug-2021	Appendix 4E and Preliminary Financial Report

27-Aug-2021	Change in substantial holding

27-Aug-2021	Change of Director's Interest - Powell

27-Aug-2021	Change of Director's Interest - Dr Geoffrey Cumming

27-Aug-2021	Change of Director's Interest - Johnston

24-Aug-2021	Notification of cessation of securities - BD1

24-Aug-2021	Appendix 2A

23-Aug-2021	BARD1 Share Purchase Plan Completed Oversubscribed

17-Aug-2021	Proof-of-Concept for SubB2M ELISA-Based Ovarian Cancer Test

30-Jul-2021	BARD1 LODGES SPP AND OPTIONS PROSPECTUS

30-Jul-2021	Appendix 4C & Quarterly Activities Report

29-Jul-2021	Appendix 2A

28-Jul-2021	BARD1 Collaborator Uni of QLD Announces Ovarian Cancer Data

23-Jul-2021	Updated Investor Presentation

23-Jul-2021	Terms of issue of Options

23-Jul-2021	Investor Presentation

23-Jul-2021	Appendix 3B

23-Jul-2021	BARD1 $15m Placement to Accelerate Cancer Diagnostic Program

21-Jul-2021	Trading Halt

7-Jul-2021	BARD1 Investor Presentation

29-Jun-2021	BARD1 Autoantibody Test Results for Ovarian Cancer Published

25-Jun-2021	SubB2M Breast Cancer Test Manuscript Submitted

4-Jun-2021	Update on Legal Proceedings

31-May-2021	R&D Tax Incentive Refund Received

25-May-2021	BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test

24-May-2021	BARD1 Files Two New Patents Protecting SubB2M & EXO-NET

19-May-2021	BARD1 EXO-NET Exosome Data Presented at ISEV2021 Conference

18-May-2021	BARD1 Launches its RUO EXO-NET Product

30-Apr-2021	Appendix 4C and Quarterly Activities Report

29-Apr-2021	Positive Results from the BARD1 Autoantibody Assay

16-Apr-2021	Appendix 3G - Long Term Incentive Options Issued to CEO

13-Apr-2021	BARD1 Signs Option Agreement for Type 3C Diabetes Test

19-Mar-2021	Appendix 2A

16-Mar-2021	Positive Results Evaluation of EXO-NET in Pancreatic Cancer

15-Mar-2021	Appendix 2A

15-Mar-2021	Australian Patent Granted for hTERT

12-Mar-2021	BARD1 Achieves hTERT Registration and First Order in Korea

2-Mar-2021	Appendix 2A

1-Mar-2021	Change in substantial holding

1-Mar-2021	Ceasing to be a substantial holder

26-Feb-2021	Appendix 4D and Half-year financial report

24-Feb-2021	Commencement of Legal Proceedings Against BARD1

23-Feb-2021	Appendix 2A

18-Feb-2021	Ceasing to be a substantial holder

17-Feb-2021	Becoming a substantial holder

15-Feb-2021	Excellent SubB2M Breast Cancer Test Data

11-Feb-2021	Outstanding SubB2M Ovarian Cancer Test Data

9-Feb-2021	Change of Auditor

29-Jan-2021	Appendix 4C & Quarterly Activities Report

28-Jan-2021	U.S. Patent Granted for NET Technology for Exosome Capture

15-Jan-2021	Final Director's Interest Notice - Dr Irminger-Finger

15-Jan-2021	Dr Irminger steps down from Board, continues as Consultant

8-Dec-2020	Change of Director's Interest Notice - Cumming

3-Dec-2020	Change of Director's Interest Notice - Powell

3-Dec-2020	Change of Director's Interest Notice - Johnston

2-Dec-2020	Final Director's Interest Notice - Helen Fisher

2-Dec-2020	Patent Granted in China for hTERT

1-Dec-2020	Further Detail on BARD1's US Sales Strategy

1-Dec-2020	Trading Halt

1-Dec-2020	Pause in Trading

27-Nov-2020	Results of Meeting

26-Nov-2020	AGM & CEO Presentations and Chairman's Transcript

26-Nov-2020	Consolidation/Split - BD1

25-Nov-2020	Helen Fisher Steps Down from BARD1 Board

23-Nov-2020	BARD1 Gains New High-volume Customer for its hTERT Test

30-Oct-2020	Appendix 4C and Quarterly Activities Report

27-Oct-2020	Notice of Annual General Meeting/Proxy Form

19-Oct-2020	Notice of AGM ASX Listing Rule 3.13.1

23-Sep-2020	Successful BARD1 Kit Evaluation

3-Sep-2020	BARD1 Awarded BTB Funding to Develop Breast Cancer Test

31-Aug-2020	Revised Securities Trading Policy

25-Aug-2020	Appendix 4G and Corporate Governance Statement

25-Aug-2020	Appendix 4E and Annual Report to Shareholders

24-Aug-2020	Change of Director's Interest - Helen Fisher

24-Aug-2020	Change of Director's Interest - Dr Geoffrey Cumming

10-Aug-2020	European Patent Validated

4-Aug-2020	Change in substantial holding

4-Aug-2020	Initial Director's Interest Notice - Fisher

4-Aug-2020	Initial Director's Interest Notice - Cumming

3-Aug-2020	Change of Director's Interest Notice - Powell

3-Aug-2020	Change of Director's Interest Notice - Johnston

3-Aug-2020	Final Directors Interest - Gunzburg

3-Aug-2020	Change in substantial holding

30-Jul-2020	Quarterly Business Update & Appendix 4C

29-Jul-2020	Appendix 2A - Issue of Scheme Shares

28-Jul-2020	BARD1 COMPLETES SIENNA ACQUISITION

28-Jul-2020	SDX: Implementation of Scheme of Arrangement

24-Jul-2020	Appointment of Chief Scientific Officer

29-Apr-2020	Quarterly Activities Report & Appendix 4C

20-Apr-2020	Receipt of R&D Tax Incentive Refund

2-Apr-2020	BARD1 Signs Contract with Griffith University

25-Feb-2020	Half Yearly Report and Accounts

30-Jan-2020	Appendix 4C Quarterly Cashflow Report

23-Jan-2020	Appendix 3Y - Cripps

23-Jan-2020	Director Appointment

10-Dec-2019	Details of Company Address

25-Nov-2019	Appendix 3B

25-Nov-2019	Appendix 3Y - Irminger-Finger

14-Nov-2019	Constitution

14-Nov-2019	Results of Meeting

14-Nov-2019	AGM Presentation

30-Oct-2019	Appendix 4C - quarterly

29-Oct-2019	Change in substantial holding

29-Oct-2019	Change in substantial holding

25-Oct-2019	Appendix 3Y - Irminger-Finger

11-Oct-2019	Notice of Annual General Meeting/Proxy Form

8-Oct-2019	Phase 3 Assay Development Milestone Reached

4-Oct-2019	Appendix 3B

3-Oct-2019	Long Term Incentives for CEO

1-Oct-2019	Appendix 3Y - Irminger-Finger

19-Aug-2019	Appendix 4G and Corporate Governance Statement

19-Aug-2019	Appendix 4E and Annual Report to Shareholders

31-Jul-2019	Quarterly Business Update and Appendix 4C

16-Jul-2019	Change in Substantial Shareholding - Irminger-Finger

16-Jul-2019	Appendix 3Y - Powell

16-Jul-2019	Appendix 3Y - Johnston

16-Jul-2019	Appendix 3Y - Irminger-Finger

16-Jul-2019	Appendix 3Y - Gunzburg

12-Jul-2019	Completion of Capital Raising Package

12-Jul-2019	Appendix 3B and Cleansing Notice 708A

10-Jul-2019	Closure of Entitlement Offer and Shortfall Notification

1-Jul-2019	Progress on Assay Development Program

26-Jun-2019	Despatch of Offer Document

19-Jun-2019	603 SSN - Merchant Funds Management Pty Ltd

19-Jun-2019	603 SSN - Jeffrey Emmanuel

19-Jun-2019	603 Initial SSN - Moggs Creek Pty Ltd ATF Moggs Creek S/F

19-Jun-2019	Letters to Shareholders

19-Jun-2019	Appendix 3X - Powell

19-Jun-2019	Appendix 3X - Johnston

19-Jun-2019	Appendix 3Z - Montgomery

18-Jun-2019	Letter to Optionholders

18-Jun-2019	Cleansing Notice Section 708(AA)

18-Jun-2019	Cleansing Notice Section 708(A)

18-Jun-2019	Offer Document

18-Jun-2019	Appendix 3B

18-Jun-2019	Capital Raising and Board Changes

14-Jun-2019	Trading Halt

3-Jun-2019	EUROPEAN PATENT VALIDATED

27-May-2019	R&D Tax Incentive Refund

1-May-2019	U.S. Patent Issued

30-Apr-2019	Appendix 4C - quarterly

1-Apr-2019	Response to ASX Price and Volume Query

28-Feb-2019	Half Yearly Report and Accounts

15-Feb-2019	Cancer Vaccine Study Results

25-Jan-2019	Quarterly Business Update and Appendix 4C

18-Dec-2018	Change in Substantial Holding

18-Dec-2018	Change of Directors Interest - Irminger-Finger

18-Dec-2018	Change of Directors Interest - Montgomery

18-Dec-2018	Change of Directors Interest - Gunzburg

18-Dec-2018	Shortfall Confirmation and Appendix 3B

12-Dec-2018	Closure of Entitlement Offer and Shortfall

3-Dec-2018	Change of Director's Interest Notice

30-Nov-2018	Results of Meeting

30-Nov-2018	AGM Presentation

27-Nov-2018	Despatch of Offer Document

20-Nov-2018	Letters to Shareholders

20-Nov-2018	Appendix 3B

19-Nov-2018	Cleansing Notice Rights Issue

19-Nov-2018	Rights Offer Document

19-Nov-2018	Company Presentation

19-Nov-2018	Appendix 3B

12-Nov-2018	Capital Raising Indicative Timetable

8-Nov-2018	Non-Renounceable Issue

7-Nov-2018	Trading Halt

7-Nov-2018	Pause In Trading

31-Oct-2018	Ceasing to be a substantial holder

31-Oct-2018	Quarterly Activities Report and Cashflow

30-Oct-2018	Notice of Annual General Meeting/Proxy Form

29-Oct-2018	Change in substantial holding

24-Oct-2018	Becoming a substantial holder

24-Oct-2018	Grant of Additional Chinese Patent Core BARD1 Patent Family

23-Oct-2018	Development of world first BARD1 Breast Cancer Test

1-Oct-2018	Appendix 4G

1-Oct-2018	Annual Report to Shareholders

20-Sep-2018	Investor Presentation and Update

10-Sep-2018	Ceasing to be a substantial holder

6-Sep-2018	Bard1 Ovarian Test Results

31-Aug-2018	Appendix 4E

21-Aug-2018	Final Director's Interest Notice

13-Aug-2018	Death of Non-Executive Director

1-Aug-2018	Quarterly Activities Report and Appendix 4C

12-Jul-2018	US Patent Issued Protecting BARD1 Ovarian Test

21-Jun-2018	Appendix 3B Release of Securities from Escrow

19-Jun-2018	Improved Performance of BARD1 Ovarian Test

8-Jun-2018	Notice under ASX Listing Rule 3.10A

18-May-2018	Reinstatement to Official Quotation

18-May-2018	Response to ASX Price Query

18-May-2018	Contract Development Agreement Signed

14-May-2018	Voluntary Suspension

10-May-2018	Trading Halt

30-Apr-2018	Quarterly Business Update and Appendix 4C

19-Apr-2018	Becoming a substantial holder

28-Mar-2018	Appendix 3B and Cleansing Statement

22-Mar-2018	Corporate Presentation

22-Mar-2018	Capital Raising

21-Mar-2018	Israeli Patent Issued in Bard1 Core Patent Family

20-Mar-2018	Trading Halt

6-Mar-2018	Additional BARD1 Ovarian Test Results

28-Feb-2018	Half Yearly Report and Accounts

20-Feb-2018	Appendix 3B (Advisor Options)

2-Feb-2018	Grant of Japanese Patent

30-Jan-2018	Quarterly Business Update and Appendix 4C

9-Jan-2018	RESULTS OF BARD1 OVARIAN CANCER STUDY

28-Nov-2017	Results of Meeting

28-Nov-2017	AGM Presentation

30-Oct-2017	Quarterly Business Update and Appendix 4C

27-Oct-2017	Notice of Annual General Meeting

4-Oct-2017	Research and Development Update

29-Sep-2017	Appendix 4G

29-Sep-2017	Annual Report to Shareholders

31-Aug-2017	Appendix 4E Preliminary Financial Results

8-Aug-2017	Publication of BARD1 Lung Cancer Test

7-Aug-2017	Appendix 3B

7-Aug-2017	Australian Patent Issued

4-Aug-2017	Completion of Share Purchase Plan

27-Jul-2017	Quarterly Activities Report & Appendix 4C

20-Jul-2017	Appointment of Dr Samuel Janes

11-Jul-2017	Completion of Capital Raising

11-Jul-2017	Appendix 3B and Cleansing Notice

11-Jul-2017	Share Purchase Plan Cleansing Statement

11-Jul-2017	Share Purchase Plan Document

5-Jul-2017	Capital Raising

3-Jul-2017	Trading Halt

28-Jun-2017	Shareholder Update

15-May-2017	Lung Cancer Study Results

28-Apr-2017	Quarterly Activities Report and Appendix 4C

18-Apr-2017	Shareholder Update

5-Apr-2017	Cancer Vaccine Collaboration

29-Mar-2017	Appendix 3B

23-Mar-2017	OVARIAN CANCER CLINICAL STUDY RESULTS

23-Mar-2017	GRANT OF U.S. PATENT

28-Feb-2017	Appendix 4D and Half Yearly Reports and Accounts

8-Feb-2017	Successful Assay Feasibility Results

31-Jan-2017	Quarterly Activities Review and Appendix 4C

8-Nov-2016	CEO Terms of Employment

7-Nov-2016	AGM RESULTS

7-Nov-2016	AGM PRESENTATION

3-Nov-2016	Appointment of CEO

31-Oct-2016	Quarterly Activities Report and Appendix 4C

19-Oct-2016	Appendix 4G

19-Oct-2016	Annual Report to Shareholders

7-Oct-2016	Notice of Annual General Meeting/Proxy Form

30-Sep-2016	Statutory Audited Financial Statements

22-Sep-2016	Company Update - Promising Result for Ovarian Cancer

31-Aug-2016	Preliminary Final Report - Appendix 4E

4-Aug-2016	Appendix 3Y - Gunzburg

2-Aug-2016	Appendix 3Y - Gunzburg

28-Jul-2016	Quarterly Activities Report and Appendix 4C

14-Jul-2016	Appendix 3Y - Gunzburg

12-Jul-2016	Appendix 3Y - Gunzburg

12-Jul-2016	Becoming a Substantial Holder - Walker

6-Jul-2016	Appendix 3Y - Gunzburg

30-Jun-2016	Appendix 3Y - Gunzburg

28-Jun-2016	Appendix 3Y - Gunzburg

21-Jun-2016	Appendix 3Y - Gunzburg

20-Jun-2016	Appendix 3Y - Gunzburg

20-Jun-2016	Becoming a substantial holder

17-Jun-2016	Confirmations to ASX

17-Jun-2016	Terms of Securities

17-Jun-2016	Confirmation in relation to restricted securities

17-Jun-2016	Securities Trading Policy

17-Jun-2016	Use of Funds Information

17-Jun-2016	Pro-forma Statement of Financial Position

17-Jun-2016	BARD1AG Financial Statements 2015

17-Jun-2016	BARD1AG Financial Statements 2014

17-Jun-2016	BARD1AG Financial Statements 2013

17-Jun-2016	Constitution

17-Jun-2016	Appendix 1A and Information Form & Checklist

17-Jun-2016	Capital Structure

17-Jun-2016	Top 20 Shareholders

17-Jun-2016	Distribution Schedule

17-Jun-2016	Pre-reinstatement Disclosure

17-Jun-2016	ASX Notice

17-Jun-2016	Reinstatement to Official Quotation - 20 June 2016

16-Jun-2016	Appendix 3Z - Collinson

16-Jun-2016	Appendix 3X - Laurent

16-Jun-2016	Appendix 3X - Irminger

16-Jun-2016	Appendix 3Y - Gunzburg

16-Jun-2016	Appendix 3B

8-Jun-2016	Receipt of Signed Restriction Agreement

3-Jun-2016	Extension to deadline for automatic removal

27-May-2016	Capital Raising Closed Oversubscribed

29-Apr-2016	Quarterly Activities Report and App 5B

7-Apr-2016	Replacement Prospectus

24-Mar-2016	Results of Meeting

24-Mar-2016	PROSPECTUS

24-Feb-2016	Notice of General Meeting

29-Jan-2016	Quarterly Activities Report and Appendix 5B

29-Jan-2016	Half Year Accounts